The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis

Redox Report

Volumn 18, Issue 4, 2013, Pages 127-133

  Ucar, Fatma ^a   Sezer, Sevilay ^b   Erdogan, Serpil ^b   Akyol, Sumeyya ^c,d   Armutcu, Ferah ^e   Akyol, Omer ^f  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c TURGUT OZAL UNIVERSITY   (Turkey)

^d GAZIOSMANPASA UNIVERSITY   (Turkey)

^e FATIH UNIVERSITY   (Turkey)

^f HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Inflammation; NAFLD; NASH; Oxidative stress

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BILIRUBIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; FERRITIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HYDROXYL RADICAL; INTERLEUKIN 6; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; URIC ACID; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MARKER; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FATTY ACID OXIDATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; IRON METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIVER CELL; LIVER CIRRHOSIS; LIVER INJURY; MITOCHONDRION; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PEROXISOME; PRIORITY JOURNAL; REVIEW; STEATOSIS; STELLATE CELL;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; IRON; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84880369408     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000213Y.0000000050     Document Type: Review

References (57)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28(4): 339-50.
2. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121(3):710-23.
3. Day CP, James OFW. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 1998;114(4):842-5.
4. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23(3):203-8.
5. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107(5):450-5.
6. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 2000;899:136-47.
7. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281(5): G1135-9.
8. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52(1):59-69.
9. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6(1):1-28.
10. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011;412(15-16): 1297-305.
11. Bonekamp NA, Völkl A, Fahimi HD, Schrader M. Reactive oxygen species and peroxisomes: struggling for balance. Biofactors 2009;35(4):346-55.
12. Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 2006;38(3):317-32.
13. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37(3):544-50.
14. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009;87(7):679-95.
15. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428-435.
16. Akyol O, Herken H, Uz E, Fadilliǒlu E, Unal S, Söǧüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(5):995-1005.
17. Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38(12):2293-301.
18. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2005;100(4):850-5.
19. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol 2003;38(1):32-8.
20. Nakashima T, Sumida Y, Furutani M, Hirohama A, Okita M, Mitsuyoshi H, et al. Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis. Hepatol Res 2005; 33(2):135-7.
21. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12(12):555-8.
22. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n- 6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106(6):635-43.
23. Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clin Biochem 2012;45(9): 610-8.
24. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42(6):928-40.
25. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38(4):999-1007.
26. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274(9):5692-700.
27. Teodoro JS, Rolo AP, Duarte FV, Simões AM, Palmeira CM. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008;8(5-6):367-76.
28. Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O. Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem 2002;277(11): 9562-9.
29. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183-92.
30. Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a cholinedeficient diet. J Cell Mol Med 2002;6(3):399-406.
31. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41(9):615-25.
32. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96(5):2461-8.
33. Armutcu F, Coskun O, Gürel A, Kanter M, Can M, Ucar F, et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005;38(6):540-7.
34. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem 2011;44(17-18):1375-9.
35. Rabelo F, Oliveira CP, Faintuch J, Mazo DF, Lima VM, Stefano JT, et al. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes Surg 2010;20(7):906-12.
36. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103(6):1372-9.
37. Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg 2009;19(5):617-24.
38. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis 2009;13(4):565-80.
39. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002;282(1):G1-5.
40. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125(2):437-43.
41. Fujita N, Takei Y. Iron Overload in Nonalcoholic Steatohepatitis. Adv Clin Chem 2011;55:105-32.
42. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37(1):56-62.
43. Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008;16(1):71-5.
44. Nagakawa Y, Williams GM, Zheng Q, Tsuchida A, Aoki T, Montgomery RA, et al. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-alpha. Hepatology 2005;42(1): 208-15.
45. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356-62.
46. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117(5):1155-63.
47. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55(4):920-32.
48. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114(2):311-31.
49. Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in nonalcoholic steatohepatitis. Hepatol Res 2009;39(3):213-22.
50. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009;18(2):424-32.
51. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012;2012:145754.
52. Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011;15(38):1-110.
53. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44(6):1167-74.
54. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II. Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38(6): 698-710.
55. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci 2013;92(2): 114-8.
56. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004;37(9):1499-507.
57. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006;130(6):1848.